Asset Dedication LLC Has $203,000 Stock Holdings in Humana Inc. (NYSE:HUM)

Asset Dedication LLC boosted its position in Humana Inc. (NYSE:HUM) by 73.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 800 shares of the insurance provider’s stock after acquiring an additional 339 shares during the period. Asset Dedication LLC’s holdings in Humana were worth $203,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Creative Financial Designs Inc. ADV increased its position in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. bought a new position in Humana in the third quarter valued at $29,000. Ashton Thomas Securities LLC purchased a new position in shares of Humana during the third quarter worth approximately $31,000. Your Advocates Ltd. LLP increased its holdings in shares of Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the period. Finally, LRI Investments LLC increased its stake in shares of Humana by 1,021.4% in the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after buying an additional 143 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

HUM has been the subject of several research reports. Leerink Partners lowered shares of Humana from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. Royal Bank of Canada lowered their price objective on shares of Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. UBS Group dropped their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, October 4th. KeyCorp began coverage on shares of Humana in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Finally, TD Cowen raised their price objective on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Nineteen research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average target price of $297.68.

Humana Trading Down 2.9 %

NYSE:HUM opened at $294.18 on Thursday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The business’s 50-day moving average is $275.44 and its two-hundred day moving average is $303.14. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $35.42 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Research analysts predict that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.